Ask the expert
ERKNet, the European Reference Network for Rare Kidney Diseases, wants to offer the exceptional expertise of its internationally renowned specialists to European patients affected by rare kidney diseases and their families.
ERKNet, the European Reference Network for Rare Kidney Diseases, wants to offer the exceptional expertise of its internationally renowned specialists to European patients affected by rare kidney diseases and their families.
World Pulmonary Hypertension Day is an annual event celebrated around the globe to raise awareness about Pulmonary Hypertension (PH), a grave disease that affects the lungs and the heart.
The next 2 to 5 May will be held at the WTC in Barcelona the XXVI annual meeting of the Catalan society of neurology.
Data from the clinical study HYPER-H21-3 show that the treatment with Dehydra TECH-CBD led to a decrease in pulmonary arterial pressure in healthy volunteers who were exposed to low levels of oxygen, conditions that replicated pulmonary hypertension (PH). This treatment, still under research, from Lexaria Bioscience is derived from cannabis and is used to treat PH.
Volem agrair-te que formis part d'aquest projecte comú. Perquè gràcies a tu i a les milers de persones que, com la teva realitzen un donatiu, col·laboreu amb Esclerosi Tuberosa a treballar cada dia.
The final results of the BREEZE study say that Tyvaso DPI, a dry powder formulation of vasodilator treprostinil under research, is safe, effective, and more comfortable than the Tyvaso nebulizer (inhaled treprostinil) approved for people with pulmonary arterial hypertension (PAH).
El pasado 20 de mayo se realizó la primera carrera.
A ASEM Catalunya podem estar satisfets d’una de les nostres activitats, La Coral. Aquest grup d’amants de la música i el cant es reuneix cada dilluns entre les 10.00 i les 11.30 a Fabra i Coats sota les ordres de Joaquín, nou responsable d’aquesta agrupació.
A continuació publiquem l’entrevista que ha sortit en el número 55 del Lligam amb el neuropediatra de l’Hospital Sant Joan de Déu, Daniel Natera.
5 d'octubre del 2021: JCR Pharmaceuticals Co, Ltd (TSE 4552; president: Shin Ashida; "JCR") ha anunciat que l'Administració d'Aliments i Medicaments dels EUA (FDA) va atorgar la designació de Via Ràpida al medicament en investigació.